ABcann Releases High Level CBD Product and Launches Initial Oils Strategy
August 28 , 2017 – Ottawa , ON – ABcann Global Corporation ( TSX-V : ABCN ) (“ ABcann ” or the “ Company ”) is pleased to announce the release of one of Canada ' s highest legal CBD : THC ( cannabidol : tetrahydrocannabinol ) ratio products available on the market by its wholly-owned subsidiary , ABcann Medicinals Inc .
The release of CBD-Med is part of the Company ' s strategy to provide a diverse range of products as it formally initiates the process to begin selling oils . CBD-Med has a ratio of 27.6:1 ( 18.5 % CBD to 0.67 % THC ), putting the product into a very select class as one of Canada ' s highest CBD products under Health Canada regulations .
In addition to formally offering this product line to its patient base , ABcann is anticipating being able to sell oils in October as it continues to diversify its product lines . Products that ABcann will have available for patients are expected to include a 1-1 THC / CBD drop , a high THC dropper and a high CBD dropper .
This new high CBD product is in addition to ABcann ' s current high CBD products : NC : Med - 18.9:1 ( 18.9 % CBD to 1 % THC ) and DC : Med - 15.4:1 ( 15.4 % CBD to 1 % THC ).
ABcann will be able to release additional product details shortly regarding the formulations of capsules and soft gels .
" The development of these products is in line with ABcann ' s corporate strategy as a premium product provider of organic , pesticide free cannabis ," says Ken Clement , Executive Chairman of ABcann . " As the Company continues to scale production capacity , our product line will expand as we strive to increase shareholder value through capturing a larger market share of the current global medical markets ."
" ABcann will continue to advance our core businesses and subsidiaries as production capacity continues to increase through our aggressive construction and expansion plans ," says Aaron Keay , Chief Executive
162
Press Release